Soy and other plant sources of phytoestrogens are among the most commonly used dietary approaches to managing menopausal symptoms. The evidence behind them is better than many clinicians appreciate, but also more mixed than the marketing suggests.

What Phytoestrogens Are

Phytoestrogens are plant compounds that bind to estrogen receptors in human tissue. They are selective estrogen receptor modulators (SERMs) in the biological sense: they activate some estrogen receptors, in some tissues, with far lower potency than estradiol: phytoestrogens bind at roughly 1/1000th the affinity of estradiol. The three main dietary classes are:

  • Isoflavones: found in soybeans, chickpeas, lentils, and other legumes. Genistein and daidzein are the most studied.
  • Lignans: found in flaxseed, sesame seeds, and whole grains. Less studied for menopause symptoms than isoflavones.
  • Coumestans: found in clover sprouts and bean sprouts. Less common in typical diets.

Soy isoflavones have the largest evidence base for menopausal symptoms and are what most clinical research refers to when assessing phytoestrogen effects.

What the Meta-Analyses Find

A meta-analysis of 19 randomised controlled trials found that soy isoflavones (median dose of 54 mg aglycone equivalents) taken for six weeks to 12 months reduced hot flash frequency by 20.6% compared with placebo, and reduced hot flash severity by 26.2%.[1]

A separate systematic review and meta-analysis specifically in perimenopausal women, published in 2025, found consistent evidence for symptom reduction including vasomotor and psychological symptoms.[2]

The effect sizes are modest. For context, HRT reduces hot flash frequency by 75–90% in most trials. Soy isoflavones produce roughly a quarter of that effect at their median dose. For women with mild to moderate symptoms who prefer a non-hormonal approach, this is a meaningful reduction. For women with severe, frequent hot flashes, it is unlikely to be sufficient.

The Time Factor Most Trials Miss

Full effect may take up to 12 months based on longer trial data.[3] Most clinical trials run only six to twelve weeks. This means the effect sizes reported in the literature are almost certainly underestimates of the full benefit with sustained use.

Women who try soy isoflavones for a month or two, notice limited benefit, and conclude they don't work may have stopped before the intervention reached maximum efficacy. Committing to at least six months before evaluating the effect is necessary to assess it fairly.

Dose and Formulation

Not all soy isoflavone preparations are equivalent. Preparations providing more than 18.8 mg of genistein are more than twice as effective at reducing hot flash frequency as lower-genistein preparations.[1] The genistein content of a supplement is clinically more relevant than the total isoflavone count on the label.

Dietary sources of soy provide isoflavones in their natural food matrix. The isoflavone content varies:

  • Edamame (100g cooked): approximately 18 mg isoflavones
  • Firm tofu (100g): approximately 25–30 mg isoflavones
  • Tempeh (100g): approximately 60 mg isoflavones
  • Soy milk (240ml): approximately 6–10 mg isoflavones

Reaching 54 mg of isoflavones daily from food is achievable but requires regular soy consumption. Supplements provide a more consistent, measurable dose but lack the other nutritional benefits of whole soy foods.

Safety

For most women: Soy isoflavones at dietary and supplementary doses in the ranges studied are safe for long-term use. They do not carry the thromboembolic risk associated with oral estrogen, and large prospective studies have not identified cardiovascular harm.

For women with hormone-receptor-positive breast cancer: The concern that phytoestrogens might stimulate ER-positive tumour growth was long considered a theoretical contraindication, but the current evidence does not support this for dietary soy intake. Multiple large observational studies, including data from Asia where soy consumption is 30–50 mg isoflavones/day versus roughly 3–5 mg in Western diets, find no increased breast cancer recurrence or mortality with soy food consumption in survivors with ER-positive disease.[4] Most current guidelines do not prohibit dietary soy for this group.

For concentrated soy isoflavone supplements at high doses, the evidence in breast cancer survivors is less complete. If you have a history of hormone-receptor-positive breast cancer or are on tamoxifen, discuss soy supplementation with your oncologist before starting.

For women on tamoxifen: There is a theoretical interaction between genistein and tamoxifen's activity at estrogen receptors. Evidence is mixed and mostly from animal studies. Women on tamoxifen should raise this with their oncologist before starting soy supplements.

What Flaxseed Adds

Flaxseed is the richest dietary source of lignans, a different class of phytoestrogens. Evidence for flaxseed and menopausal symptoms is weaker than for soy isoflavones, but some trials have found modest reductions in hot flash frequency with regular consumption: one randomised trial found that 40 g of ground flaxseed daily reduced hot flash frequency by roughly 50% over six weeks, though effect sizes in the literature vary and larger confirmatory trials are needed. Flaxseed also provides alpha-linolenic acid (ALA, an omega-3 precursor), fibre, and other compounds with anti-inflammatory effects, which are grounds for including it in a menopause-supportive diet independent of the phytoestrogen effect.

Grinding whole flaxseed before use makes the lignans and ALA bioavailable; whole seeds pass largely undigested. One to two tablespoons of ground flaxseed daily is a practical dose.

Practical Summary

Soy isoflavones have a genuine, evidence-based effect on vasomotor symptoms. The effect is modest compared to HRT, but meaningful for women with mild-to-moderate symptoms. Three conditions for seeing results:

  1. Use consistently for at least six months before assessing efficacy
  2. Aim for at least 50–60 mg of isoflavones daily from diet or supplements
  3. Prioritise genistein-rich sources (tempeh, genistein-standardised supplements)

Meeting all three conditions gives the intervention its best chance of producing a measurable reduction in hot flash frequency.

For women who cannot use HRT, or who prefer to start with a dietary approach, soy isoflavones are a reasonable first-line option for mild-to-moderate vasomotor symptoms, with a safety profile appropriate for most women.

## References [1] Howes, L. G., Howes, J. B., Knight, D. C. (2006). Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas, 55(3), 203-211.

[2] Qin, Y., et al. (2025). Effects of soy isoflavones on menopausal symptoms in perimenopausal women: a systematic review and meta-analysis. Frontiers in Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC12296567/

[3] Williamson-Hughes, P. S., Flickinger, B. D., Messina, M. J., Empie, M. W. (2006). Isoflavone supplements containing predominantly genistein reduce hot flash symptoms. Menopause, 13(5), 831-839. Cited in: Soybean isoflavones warrant greater consideration as treatment. https://pubmed.ncbi.nlm.nih.gov/25482479/

[4] Messina, M. (2016). Soy and health update: Evaluation of the clinical and epidemiologic literature. Nutrients, 8(12), 754. https://doi.org/10.3390/nu8120754